Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 01, 2016 16:01 ET | Source: Repros Therapeutics Inc.

Repros Provides Update on EU Submission of Enclomiphene for the Treatment of Secondary Hypogonadism and 3 Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men

EU submission on track with anticipated registration decision expected Fall 2017 UK designated as rapporteur and France as co-rapporteur for the centralized review of the enclomiphene marketing...
May 18, 2016 16:01 ET | Source: Repros Therapeutics Inc.

Repros Reports Positive Clinical Data for Oral Proellex® in Women With Severe Menstrual Bleeding Due to Uterine Fibroids

Primary endpoint of induction of amenorrhea met for the pooled oral doses compared to placebo, p=0.0004Proellex®-treated subjects reported a median 100% (mean 95%) reduction in diary reports of...
May 16, 2016 16:00 ET | Source: Repros Therapeutics Inc.

Repros Announces the Appointment of Mr. Patrick Fourteau as Chairman of the Board

THE WOODLANDS, Texas, May 16, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that it has appointed Mr. Patrick Fourteau to its Board of Directors, where he will...
May 10, 2016 09:15 ET | Source: Repros Therapeutics Inc.

Repros Therapeutics Inc.® Reports First Quarter 2016 Financial Results

THE WOODLANDS, Texas, May 10, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the first quarter ended March 31, 2016. Financial Results ...
April 12, 2016 16:01 ET | Source: Repros Therapeutics Inc.

Repros Reports Positive Clinical Data for Vaginal Proellex® in Women With Severe Menstrual Bleeding Due to Uterine Fibroids

Primary endpoint of induction of amenorrhea met for both vaginal doses compared to placebo, p<0.0011Proellex®-treated subjects reported a median 100% reduction in diary reports of menstrual...
March 15, 2016 16:01 ET | Source: Repros Therapeutics Inc.

Repros Announces Initiation of Formal Approval Process by the European Medicines Agency

THE WOODLANDS, Texas, March 15, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that it has formally activated the process for obtaining marketing authorization...
March 14, 2016 09:15 ET | Source: Repros Therapeutics Inc.

Repros Therapeutics Inc.® Reports Fourth Quarter and Year End 2015 Financial Results

THE WOODLANDS, Texas, March 14, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the fourth quarter and year ended December 31, 2015. ...
February 16, 2016 16:01 ET | Source: Repros Therapeutics Inc.

Repros Completes Randomization of Enclomiphene Phase 2 Proof of Concept Study in Obese Secondary Hypogonadal Men

Phase 2 proof of concept study in obese men to assess drug impact on metabolic and quality of life parameters under a rigorous diet and exercise regimen Analyses at 3, 6 and 12 month time...
February 08, 2016 16:01 ET | Source: Repros Therapeutics Inc.

Repros Holds Meeting With FDA to Discuss Complete Response Letter for Enclomiphene in the Treatment of Secondary Hypogonadism

THE WOODLANDS, Texas, Feb. 08, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that on February 4, 2016, the Company attended a productive meeting with FDA...
January 11, 2016 09:15 ET | Source: Repros Therapeutics Inc.

Repros Announces Court of Appeals’ Affirmation of Summary Judgment in Favor of the Company

THE WOODLANDS, Texas, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that the United States Court of Appeals for the Federal Circuit summarily affirmed...